• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Meta-Analysis: Does Baseline BP Impact Cardiovascular Risk When Lowering Systolic BP?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • The Blood Pressure Lowering Treatment Trialists’ Collaborators (The Lancet, 2021) investigated whether the initial baseline systolic blood pressure impacts the effect of blood-pressure-lowering treatment on cardiovascular risk

METHODS:

  • Meta-analysis of individual participant-level data
    • The Blood Pressure Lowering Treatment Trialists’ Collaboration
  • Study inclusion criteria
    • RCTs that had at least 1000 persons-years of follow-up in each group
    • Studies that included data on pharmacological blood-pressure-lowering medications vs placebo or other classes of blood-pressure-lowering medications
    • Excluded: Trials only in setting of heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings
  • Exposures
    • Cardiovascular disease: Stroke | MI | Ischemic heart disease
      • Overall (all BP baselines)
      • Across seven systolic blood pressure categories (ranging from <120 to ≥170 mm Hg)
  • Primary outcome
    • Major cardiovascular event analyzed as per intention to treat
    • Defined as a composite of: Fatal and non-fatal stroke | Fatal or non-fatal MI or ischaemic heart disease | Heart failure causing death or requiring admission to hospital

RESULTS:

  • 48 trials | 344,716 participants
    • With previous CVD: 157,728 individuals
      • Pre-randomization blood pressure: 146/84 mm Hg
    • Without previous CVD: 186,988 individuals
      • Pre-randomization blood pressure: 157/89 mm Hg
  • Systolic blood pressure of <130 mm Hg at baseline
    • With previous CVD: 19.8%
    • Without previous CVD: 8.0%
  • Effects of blood-pressure-lowering treatment were proportional to the intensity of systolic blood pressure reduction
  • Major CV events after median 4.15 years of follow-up: 12.3%
  • Incidence rate for developing a major cardiovascular event per 1000 person-years
    • With previous cardiovascular disease at baseline
      • Comparator group: 39.7 (95% CI, 39.0 to 40.5)
      • Intervention group: 36.0 (95% CI, 35.3 to 36.7)
    • Without previous cardiovascular disease at baseline
      • Comparator group: 31.9 (95% CI, 31.3 to 32.5)
      • Intervention group: 25.9 (95% CI, 25.4 to 26.4)
  • A reduction of systolic blood pressure by 5 mm Hg was associated with a reduced risk of a major CV event for participants both with and without previous CVD
    • With previous CVD: hazard ratio (HR) 0.89 (95% CI, 0.86 to 0.92)
    • Without previous CVD: HR 0.91 (95% CI, 0.89 to 0.94)
  • In stratified analyses, there was no reliable evidence of heterogeneity of treatment effects on major cardiovascular events by
    • Baseline cardiovascular disease status
    • Systolic blood pressure categories

CONCLUSION:

  • Reducing systolic blood pressure by 5 mm Hg reduced the risk of major cardiovascular events by about 10%, irrespective of initial systolic baseline
    • Results were not dependent on a history of cardiovascular disease
    • Same results were obtained among those with normal or high–normal blood pressure values
  • Lowering blood pressure may be effective for primary and secondary prevention of major cardiovascular disease even at blood pressure levels not usually considered for treatment by current guidelines
  • The authors conclude

…greater relative risk reductions are expected with larger blood pressure reductions, as is the case with multiple blood pressure lowering drugs

Thus, the feasibility of modest systolic blood pressure reductions of about 15 mm Hg across all blood pressure strata, as shown in another BPLTTC study together with the consistency of effects shown in the present study, questions the scientific validity of defining a common blood pressure target for all participants

Learn More – Primary Sources:

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Cochrane Review: Do Omega-3 Fatty Acids Reduce Cardiovascular Disease? 
A 21 RCT Meta-analysis: Do Vitamin D Supplements Reduce Risk of Cardiovascular Disease?
Does Low-Dose Aspirin Reduce Risk of First Cardiovascular Events in Individuals at Moderate Risk?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site